00:00Naomi, could you just tell us about the shift that's taking place right now in the global market for weight loss drugs?
00:04So, I mean, we're going really from a few years where Novo Nordisk couldn't make enough semaglutide to supply the market in the U.S., let alone in the rest of the world, to a time when in a growing number of countries there will be a lot of generic competitors on the market and people will suddenly have access that they never had before to super powerful obesity medicines.
00:34So it's from a consumer standpoint, from a public health standpoint, from a market, new drug market standpoint, it's really a super interesting moment right now.
00:52There's already been a lot of reporting in the U.S., in Europe, in the Western world about how drugs like Ozempic can change, shift cultures, change the way people think about their lives, change about the way people think about their health, their social habits.
01:10And there's still a lot we don't know about the long-term effects of these drugs.
01:15And now this next chapter of these drugs is getting written in the Global South, where a lot of adults living with obesity is now going to have ready, affordable access to these drugs.
01:31And in a sense, we are going to find out what will happen when all these drugs are suddenly available to so many other people living in such different cultures and such different societal conditions.
Comments